Amneal gains FDA greenlight to develop Ciprodex generic for ear infections
2024-03-26
上市批准快速通道合格传染病产品
Preview
来源: Pharmaceutical Technology
Amneal aims to develop an affordable, complex, high-value product for bacterial ear infections. Credits: goodlux/Shutterstock.com.
Amneal Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved an abbreviated new drug application (ANDA) for its ciprofloxacin and dexamethasone otic suspension, a generic drug of Novartis’ Ciprodex (ciprofloxacin/dexamethasone), for the treatment of ear infections.
With the FDA approval, the New Jersey-based pharma company will develop an affordable, complex, and high-value product that reflects the “diversification of [the] business” and its evolving portfolio, said Amneal’s generics executive vice-president Andy Boyer in the 25 March press release.
An approved ANDA allows a sponsor to manufacture and market a safe and effective generic product at a lower cost than the brand-name product it references.
Ciprodex is designed to prevent bacterial DNA replication and the growth of new bacteria via the antibiotic ciprofloxacin. It suppresses inflammation by inhibiting the synthesis of cytokines associated with inflammation. As per its label, the drug is indicated to treat infections caused by susceptible isolates of the designated microorganisms in acute otitis media (AOM) and acute otitis externa (AOE) in patients aged six months and older.
Novartis reported a 62% rise in net income in 2023, increasing from $6.04bn to $8.6bn on constant currencies.
See Also:
J&J’s nipocalimab gains FDA fast track status for FNAIT risk reduction
Preview
来源: Pharmaceutical Technology
Takeda’s ADZYNMA gains Japanese approval for cTTP treatment
Preview
来源: Pharmaceutical Technology
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。